Zhejiang Garden BiopharmaceuticalLtd Valuation

Is 300401 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 300401 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 300401 (CN¥14.81) is trading above our estimate of fair value (CN¥1.78)

Significantly Below Fair Value: 300401 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 300401?

Key metric: As 300401 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 300401. This is calculated by dividing 300401's market cap by their current earnings.
What is 300401's PE Ratio?
PE Ratio	28.3x
Earnings	CN¥284.89m
Market Cap	CN¥8.05b

300401 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	7.4x
Enterprise Value/EBITDA	18.8x
PEG Ratio	0.8x

Price to Earnings Ratio vs Peers

How does 300401's PE Ratio compare to its peers?

The above table shows the PE ratio for 300401 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	45.3x
000650 Renhe PharmacyLtd	18.3x	n/a	CN¥8.1b
000597 Northeast Pharmaceutical Group	21.1x	n/a	CN¥7.3b
002550 Changzhou Qianhong BiopharmaLTD	25.9x	16.7%	CN¥7.6b
600812 North China Pharmaceutical Company.Ltd	115.9x	n/a	CN¥9.2b
300401 Zhejiang Garden BiopharmaceuticalLtd	28.3x	34.7%	CN¥8.0b

Price-To-Earnings vs Peers: 300401 is good value based on its Price-To-Earnings Ratio (28.3x) compared to the peer average (45.3x).

Price to Earnings Ratio vs Industry

How does 300401's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap

No more companies available in this PE range

0 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: 300401 is good value based on its Price-To-Earnings Ratio (28.3x) compared to the CN Pharmaceuticals industry average (31.1x).

Price to Earnings Ratio vs Fair Ratio

What is 300401's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

300401 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	28.3x
Fair PE Ratio	32.5x

Price-To-Earnings vs Fair Ratio: 300401 is good value based on its Price-To-Earnings Ratio (28.3x) compared to the estimated Fair Price-To-Earnings Ratio (32.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

China Resources Double-Crane PharmaceuticalLtd

CN¥21.4b

China Resources Double-Crane Pharmaceutical Co.,Ltd.

600062

CN¥20.80

-3.9%

12.1%

Jiangsu Kanion PharmaceuticalLtd

CN¥8.1b

Researches and develops, produces, and sells Chinese medicines.

600557

CN¥14.29

-4.2%

-23.6%

Dong-E-E-JiaoLtd

CN¥36.4b

Research and development, production, and sale of Ejiao and a series of Chinese patent medicines, health foods, and foods.

423

CN¥56.60

-3.0%

13.2%